Top

BMC Immunology

Published in:

Open Access 01-12-2019 | Multiple Myeloma | Research article

Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

Authors: Ida Marie Rundgren, Elisabeth Ersvær, Aymen Bushra Ahmed, Anita Ryningen, Øystein Bruserud

Published in: BMC Immunology | Issue 1/2019

Abstract

Background

Induction therapy of multiple myeloma patients prior to autologous stem cell transplantation has changed from conventional chemotherapy to treatment based on proteasome inhibitors or immunomodulatory drugs. We used flow cytometry to analyze total monocyte and monocyte subset (classical, intermediate and non-classical monocytes) peripheral blood levels before and following auto-transplantation for a consecutive group of myeloma patients who had received the presently used induction therapy.

Results

The patients showed normal total monocyte concentrations after induction/stem cell mobilization, but the concentrations of classical monocytes were increased compared with healthy controls. Melphalan conditioning reduced the levels of total CD14⁺ as well as classical and non-classical monocytes, whereas intermediate monocytes were not affected. Thus, melphalan has a non-random effect on monocyte subsets. Melphalan had a stronger effect on total and classical monocyte concentrations for those patients who had received induction therapy including immunomodulatory drugs. Total monocytes and monocyte subset concentrations decreased during the period of pancytopenia, but monocyte reconstitution occurred before hematopoietic reconstitution. However, the fractions of various monocyte subsets varied considerably between patients.

Conclusions

The total level of circulating monocytes is normalized early after auto-transplantation for multiple myeloma, but pre- and post-transplant levels of various monocyte subsets show considerable variation between patients.

Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):E538–E48.CrossRef

Kyle RA, Gertz MA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.CrossRef

Drayson M, Tang LX, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900–2. https://doi.org/10.1182/blood.V97.9.2900.CrossRefPubMed

Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(10):999–1009. https://doi.org/10.1002/ajh.23810.CrossRefPubMed

Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–19. https://doi.org/10.1016/j.mayocp.2015.11.007.CrossRefPubMedPubMedCentral

Guillaume T, Rubinstein DB, et al. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92(5):1471–90.CrossRef

Wichert S, Pettersson A, et al. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma. Exp Hematol. 2016;44(5):342–51.e5. https://doi.org/10.1016/j.exphem.2016.01.002.CrossRefPubMed

Weinberger A, Klein T, et al. Clinical and genetic characteristics of late-onset Behcet’s disease. Adv Exp Med Biol. 2003;528:99–101. https://doi.org/10.1007/0-306-48382-3_20.CrossRefPubMed

Swirski FK, Nahrendorf M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612–6. https://doi.org/10.1126/science.1175202.CrossRefPubMedPubMedCentral

10.

Jakubzick CV, Randolph GJ, et al. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. 2017;17(6):349–62. https://doi.org/10.1038/nri.2017.28.CrossRefPubMed

11.

Arderiu G, Espinosa S, et al. Tissue factor variants induce monocyte transformation and transdifferentiation into endothelial cell-like cells. J Thromb Haemost. 2017. https://doi.org/10.1111/jth.13751.CrossRef

12.

Costa F, Vescovini R, et al. Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget. 2017;8(32):53053–67. https://doi.org/10.18632/oncotarget.18085.CrossRefPubMedPubMedCentral

13.

Passlick B, Flieger D, et al. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74(7):2527–34.CrossRef

14.

Patel AA, Zhang Y, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. 2017;214(7):1913–23. https://doi.org/10.1084/jem.20170355.CrossRefPubMedPubMedCentral

15.

Ziegler-Heitbrock L, Ancuta P, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74–80. https://doi.org/10.1182/blood-2010-02-258558.CrossRefPubMed

16.

Boyette LB, Macedo C, et al. Phenotype, function, and differentiation potential of human monocyte subsets. PLoS One. 2017;12(4):e0176460. https://doi.org/10.1371/journal.pone.0176460.CrossRefPubMedPubMedCentral

17.

Giuliani N, Rizzoli V, et al. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood. 2006;108(13):3992–6. https://doi.org/10.1182/blood-2006-05-026112.CrossRefPubMed

18.

Petitprez V, Royer B, et al. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Int J Lab Hematol. 2015;37(1):29–35. https://doi.org/10.1111/ijlh.12216.CrossRefPubMed

19.

Silbermann R, Bolzoni M, et al. Bone marrow monocyte−/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2014;28(4):951–4. https://doi.org/10.1038/leu.2013.385.CrossRefPubMed

20.

Bolzoni M, Ronchetti D, et al. IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica. 2017;102(4):773–84. https://doi.org/10.3324/haematol.2016.153841.CrossRefPubMedPubMedCentral

21.

Bekkering S, Joosten LAB, et al. The Epigenetic Memory of Monocytes and Macrophages as a Novel Drug Target in Atherosclerosis. Clin Ther. 2015;37(4):914–23. https://doi.org/10.1016/j.clinthera.2015.01.008.CrossRefPubMed

22.

Hamon MA, Quintin J. Innate immune memory in mammals. Semin Immunol. 2016;28(4):351–8. https://doi.org/10.1016/j.smim.2016.05.003.CrossRefPubMed

23.

Quintin J, Saeed S, et al. Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes. Cell Host Microbe. 2012;12(2):223–32. https://doi.org/10.1016/j.chom.2012.06.006.CrossRefPubMed

24.

Fiorcari S, Martinelli S, et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica. 2015;100(2):253–62. https://doi.org/10.3324/haematol.2014.113217.CrossRefPubMedPubMedCentral

25.

Shah N, Callander N, et al. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Tr. 2015;21(7):1155–66. https://doi.org/10.1016/j.bbmt.2015.03.002.CrossRef

26.

Porrata LF, Gertz MA, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2004;18(6):1085–92. https://doi.org/10.1038/sj.leu.2403341.CrossRefPubMed

27.

Porrata LF, Gastineau DA, et al. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leukemia Lymphoma. 2003;44(6):997–1000. https://doi.org/10.1080/1042819031000077089.CrossRefPubMed

28.

Porrata LF, Gertz MA, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98(3):579–85. https://doi.org/10.1182/blood.V98.3.579.CrossRefPubMed

29.

Rueff J, Medinger M, et al. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant. 2014;20(6):896–9. https://doi.org/10.1016/j.bbmt.2014.03.007.CrossRefPubMed

30.

Hatfield KJ, Melve GK, et al. Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors. Metabolomics. 2017;13(1):2. https://doi.org/10.1007/s11306-016-1139-x.CrossRefPubMed

31.

Melve GK, Ersvaer E, et al. Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets. Front Immunol. 2018;9:845. https://doi.org/10.3389/fimmu.2018.00845.CrossRefPubMedPubMedCentral

32.

Impola U, Larjo A, et al. Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML. Front Immunol. 2016;7:523. https://doi.org/10.3389/fimmu.2016.00523.CrossRefPubMedPubMedCentral

33.

Shantsila E, Tapp LD, et al. The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. Eur J Clin Invest. 2012;42(8):832–9. https://doi.org/10.1111/j.1365-2362.2012.02656.x.CrossRefPubMed

34.

Statland BE, Winkel P, et al. Evaluation of Biologic Sources of Variation of Leukocyte Counts and Other Hematologic Quantities Using Very Precise Automated Analyzers. Am J Clin Pathol. 1978;69(1):48–54.CrossRef

35.

Saunders AM. Sources of physiological variation in differential leukocyte counting. Blood Cells. 1985;11(1):31–48.PubMed

36.

Smaaland R, Sothern RB, et al. Rhythms in human bone marrow and blood cells. Chronobiol Int. 2002;19(1):101–27. https://doi.org/10.1081/Cbi-120002594.CrossRefPubMed

37.

Rundgren IM, Bruserud O, et al. Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood. J Immunol Methods. 2018;461:53–62. https://doi.org/10.1016/j.jim.2018.06.003.CrossRefPubMed

38.

Callander NS, Rathouz PJ, et al. Recovery Of Natural Killer Cells and Monocyte Subsets Following Autologous Peripheral Blood Stem Cell Transplantation Predicts Longer Progression Free Survival Among Multiple Myeloma Patients. Blood. 2013;122(21):2126.CrossRef

39.

Rosean TR, Tompkins VS, et al. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014;59(1–3):188–202. https://doi.org/10.1007/s12026-014-8528-x.CrossRefPubMedPubMedCentral

40.

Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med. 2011;208(3):421–8. https://doi.org/10.1084/jem.20110132.CrossRefPubMedPubMedCentral

41.

Fleming S, Harrison SJ, et al. The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. Cl Lymph Myelom Leuk. 2014;14(4):291–6. https://doi.org/10.1016/j.clml.2014.02.001.CrossRef

42.

Lonial S, San Miguel JF. Induction Therapy for Newly Diagnosed Multiple Myeloma. J Natl Compr Canc Ne. 2013;11(1):19–28. https://doi.org/10.6004/jnccn.2013.0005.CrossRef

43.

Dhakal B, Brazauskas R, et al. Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2015;21(2):S163–S4. https://doi.org/10.1016/j.bbmt.2014.11.239.CrossRef

44.

Vasileiou S, Baltadakis I, et al. Ex Vivo Induction of Multiple Myeloma-specific Immune Responses by Monocyte-derived Dendritic Cells Following Stimulation by Whole-tumor Antigen of Autologous Myeloma Cells. J Immunother. 2017;40(7):253–64.CrossRef

45.

Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22(22):5428–33. https://doi.org/10.1158/1078-0432.Ccr-16-0866.CrossRefPubMedPubMedCentral

46.

Chantry A, Kazmi M, et al. Guidelines for the use of imaging in the management of patients with myeloma. Brit J Haematol. 2017;178(3):380–93. https://doi.org/10.1111/bjh.14827.CrossRef

47.

Mosevoll KA, Akkok CA, et al. Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 2013;15(7):850–60. https://doi.org/10.1016/j.jcyt.2013.02.008.CrossRefPubMed

48.

Akkok CA, Hervig T, et al. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 2011;13(10):1259–68. https://doi.org/10.3109/14653249.2011.605117.CrossRefPubMed

49.

Bakken AM, Bruserud O, et al. No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide. J Hematoth Stem Cell. 2003;12(3):351–8. https://doi.org/10.1089/152581603322023089.CrossRef

50.

Abrahamsen JF, Rusten L, et al. Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide. Transfusion. 2004;44(5):785–9. https://doi.org/10.1111/j.1537-2995.2004.03336.x.CrossRefPubMed

Title: Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients
Authors: Ida Marie Rundgren
Elisabeth Ersvær
Aymen Bushra Ahmed
Anita Ryningen
Øystein Bruserud
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Multiple Myeloma
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: BMC Immunology / Issue 1/2019
Electronic ISSN: 1471-2172
DOI: https://doi.org/10.1186/s12865-019-0323-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

Abstract

Background

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Genetic polymorphisms and epigenetic regulation of survivin encoding gene, BIRC5, in multiple sclerosis patients

Low pre-transplant levels of mannose-binding lectin are associated with viral infections and mortality after haematopoietic allogeneic stem cell transplantation

Phenotypic and functional stability of leukocytes from human peripheral blood samples: considerations for the design of immunological studies

Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients

Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD

Comprehensive analyses of long non-coding RNA expression profiles by RNA sequencing and exploration of their potency as biomarkers in psoriatic arthritis patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page